Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.
Aerin's mission is to provide ENT physicians with tissue-sparing solutions for the treatment of nasal airway conditions to improve the quality of life of their patients.
Aerin Medical was founded in 2011 by Andrew Frazier and Scott Wolf. The company is headquartered in Sunnyvale, California, with an office in Austin, Texas.
Aerin's FDA-cleared products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary, temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with an in-office procedure performed with local anesthetic
VivAer was launched in the U.S. in 2018, and is used to treat nasal obstruction, a condition that affects 20 million Americans. RhinAer was launched in the U.S. in 2020 for the treatment of chronic rhinitis.
Aerin Medical's devices has been used to treat more than 60,000 patients.
Aerin is backed by OrbiMed, Ally Bridge Group, Questa Capital, KCK MedTech, CRG LP, and others. The company raised $60M in a new round on Jun 16, 2022. This brings Aerin's total funding to $190.5M to date.